116 related articles for article (PubMed ID: 25425687)
21. A new mechanism of leukemia drug resistance?
Williams DA
N Engl J Med; 2007 Jul; 357(1):77-8. PubMed ID: 17611211
[No Abstract] [Full Text] [Related]
22. Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
Styczynski J; Kurylak A; Wysocki M
Anticancer Res; 2005; 25(3B):2253-8. PubMed ID: 16158972
[TBL] [Abstract][Full Text] [Related]
23. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
24. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Hawkins LM; Jayanthan AA; Narendran A
Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
[TBL] [Abstract][Full Text] [Related]
25. [Modulation of glucocorticoid sensitivity in acute lymphoblastic leukemia: Pyr3, a new therapeutic tool?].
Abdoul-Azize S; Dubus I; Vannier JP
Med Sci (Paris); 2017 Feb; 33(2):130-132. PubMed ID: 28240201
[No Abstract] [Full Text] [Related]
26. St Jude researchers use DNA chips to determine how leukemia cells responds to different drug treatments.
Pharmacogenomics; 2003 May; 4(3):244. PubMed ID: 12774778
[No Abstract] [Full Text] [Related]
27. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.
Wei G; Twomey D; Lamb J; Schlis K; Agarwal J; Stam RW; Opferman JT; Sallan SE; den Boer ML; Pieters R; Golub TR; Armstrong SA
Cancer Cell; 2006 Oct; 10(4):331-42. PubMed ID: 17010674
[TBL] [Abstract][Full Text] [Related]
28. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis and modeling of glucocorticoid-controlled gene expression.
Chen DW; Lynch JT; Demonacos C; Krstic-Demonacos M; Schwartz JM
Pharmacogenomics; 2010 Nov; 11(11):1545-60. PubMed ID: 21121775
[TBL] [Abstract][Full Text] [Related]
30. Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia.
Mansha M; Carlet M; Ploner C; Gruber G; Wasim M; Wiegers GJ; Rainer J; Geley S; Kofler R
Leuk Res; 2010 Apr; 34(4):529-34. PubMed ID: 19631983
[TBL] [Abstract][Full Text] [Related]
31. Mutual antagonism between glucocorticoid and canonical Wnt signaling pathways in B-cell acute lymphoblastic leukemia.
Bergeron BP; Barnett KR; Bhattarai KR; Mobley RJ; Hansen BS; Brown A; Kodali K; High AA; Jeha S; Pui CH; Peng J; Pruett-Miller SM; Savic D
Blood Adv; 2023 Aug; 7(15):4107-4111. PubMed ID: 37289547
[No Abstract] [Full Text] [Related]
32. Quest for effective agents to combat T-cell acute lymphoblastic leukemia.
Pui CH
Eur J Cancer; 2005 Jun; 41(9):1243-5. PubMed ID: 15939259
[No Abstract] [Full Text] [Related]
33. Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia.
Gu L; Yi Z; Zhang Y; Ma Z; Zhu Y; Gao J
Oncotarget; 2017 May; 8(19):30978-30991. PubMed ID: 28415682
[TBL] [Abstract][Full Text] [Related]
34. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia.
Bergeron BP; Diedrich JD; Zhang Y; Barnett KR; Dong Q; Ferguson DC; Autry RJ; Yang W; Hansen BS; Smith C; Crews KR; Fan Y; Pui CH; Pruett-Miller SM; Relling MV; Yang JJ; Li C; Evans WE; Savic D
Leukemia; 2022 Oct; 36(10):2374-2383. PubMed ID: 36028659
[TBL] [Abstract][Full Text] [Related]
35. Corticosteroid resistance and disease.
DeRijk R; Sternberg EM
Ann Med; 1997 Feb; 29(1):79-82. PubMed ID: 9073327
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of blast cell sensitivity to low-intensity laser radiation and chemotherapeutic drugs].
Karu TI; Riabykh TP; Sidorova TA; Dobrynin IaV
Dokl Akad Nauk; 1997 Mar; 353(1):114-7. PubMed ID: 9273047
[No Abstract] [Full Text] [Related]
37. Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Salvador C; Meister B; Crazzolara R; Kropshofer G
Pediatr Blood Cancer; 2012 Oct; 59(4):771. PubMed ID: 22619026
[No Abstract] [Full Text] [Related]
38. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Cancer; 2006 Dec; 95(11):1537-44. PubMed ID: 17117183
[TBL] [Abstract][Full Text] [Related]
39. Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance.
Lauten M; Schrauder A; Kardinal C; Harbott J; Welte K; Schlegelberger B; Schrappe M; von Neuhoff N
Leukemia; 2006 May; 20(5):820-6. PubMed ID: 16541142
[TBL] [Abstract][Full Text] [Related]
40. [Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].
Xu JY; Luo JM
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Aug; 19(8):945-949. PubMed ID: 28774373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
